PlainRecalls
FDA Drug Critical Class I Ongoing

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22

Reported: December 13, 2023 Initiated: November 22, 2023 #D-0144-2024

Product Description

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22

Reason for Recall

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Details

Units Affected
6,997 bottles
Distribution
Nationwide within the United States
Location
East Hanover, NJ

Frequently Asked Questions

What product was recalled?
SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22. Recalled by Novartis Pharmaceuticals Corporation. Units affected: 6,997 bottles.
Why was this product recalled?
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals
Which agency issued this recall?
This recall was issued by the FDA Drug on December 13, 2023. Severity: Critical. Recall number: D-0144-2024.